The Membrane-spanning Domains of Caveolins-1 and -2 Mediate the Formation of Caveolin Hetero-oligomers

The mammalian caveolin gene family consists of caveolins-1, -2, and -3. The expression of caveolin-3 is muscle-specific. In contrast, caveolins-1 and -2 are co-expressed, and they form a hetero-oligomeric complex in many cell types, with particularly high levels in adipocytes, endothelial cells, and fibroblasts. These caveolin hetero-oligomers are thought to represent the functional assembly units that drive caveolae formation in vivo. Here, we investigate the mechanism by which caveolins-1 and -2 form hetero-oligomers. We reconstituted this reciprocal interactionin vivo and in vitro using a variety of complementary approaches, including the generation of glutathioneS-transferase fusion proteins and synthetic peptides. Taken together, our results indicate that the membrane-spanning domains of both caveolins-1 and -2 play a critical role in mediating their ability to interact with each other. This is the first demonstration that these unusual membrane-spanning regions found in the caveolin family play a specific role in protein-protein interactions.

[1]  J. Engelman,et al.  Sequence and detailed organization of the human caveolin‐1 and ‐2 genes located near the D7S522 locus (7q31.1) , 1999, FEBS letters.

[2]  J. Engelman,et al.  Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. , 1998, American journal of human genetics.

[3]  J. Engelman,et al.  Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis* , 1998, The Journal of Biological Chemistry.

[4]  J. Engelman,et al.  Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade , 1998, The EMBO journal.

[5]  J. Engelman,et al.  Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers , 1998, FEBS letters.

[6]  J. Engelman,et al.  Mutational analysis of caveolin‐induced vesicle formation , 1998, FEBS letters.

[7]  J. Engelman,et al.  Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) , 1998, FEBS letters.

[8]  F. Zara,et al.  Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy , 1998, Nature Genetics.

[9]  M. Lisanti,et al.  Caveolins, a Family of Scaffolding Proteins for Organizing “Preassembled Signaling Complexes” at the Plasma Membrane* , 1998, The Journal of Biological Chemistry.

[10]  K. Uzawa,et al.  Localization of a tumour‐suppressor gene associated with human oral cancer on 7q31.1 , 1998, International journal of cancer.

[11]  P. Scheiffele,et al.  Caveolin-1 and -2 in the Exocytic Pathway of MDCK Cells , 1998, The Journal of cell biology.

[12]  Haojie Huang,et al.  Fish mapping of YAC clones at human chromosomal band 7q31.2: Identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer , 1998, Genes, chromosomes & cancer.

[13]  E. Bergstralh,et al.  Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer , 1998, Genes, chromosomes & cancer.

[14]  M. Lisanti,et al.  Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveolins , 1997, The Journal of Biological Chemistry.

[15]  David I. Smith,et al.  Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas , 1997, Oncogene.

[16]  E. V. van Donselaar,et al.  Cell-type and Tissue-specific Expression of Caveolin-2 , 1997, The Journal of Biological Chemistry.

[17]  Charles C. Wykoff,et al.  Recombinant Expression of Caveolin-1 in Oncogenically Transformed Cells Abrogates Anchorage-independent Growth* , 1997, The Journal of Biological Chemistry.

[18]  M. Lisanti,et al.  Molecular and cellular biology of caveolae paradoxes and plasticities. , 1997, Trends in cardiovascular medicine.

[19]  Carl W. Miller,et al.  Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer , 1997, Genes, chromosomes & cancer.

[20]  Tsuneya Ikezu,et al.  Identification of Peptide and Protein Ligands for the Caveolin-scaffolding Domain , 1997, The Journal of Biological Chemistry.

[21]  M. Lisanti,et al.  Mutational Analysis of the Properties of Caveolin-1 , 1997, The Journal of Biological Chemistry.

[22]  T. Katada,et al.  Identification, Sequence, and Expression of an Invertebrate Caveolin Gene Family from the Nematode Caenorhabditis elegans , 1997, The Journal of Biological Chemistry.

[23]  S. S. Koh,et al.  Baculovirus-based Expression of Mammalian Caveolin in Sf21 Insect Cells , 1996, The Journal of Biological Chemistry.

[24]  S. Scherer,et al.  Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. , 1996, Oncogene.

[25]  A. Scarpa,et al.  Chromosome 7q allelic losses in pancreatic carcinoma. , 1996, Cancer research.

[26]  M. Lisanti,et al.  Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.

[27]  M. Lisanti,et al.  Phosphorylation of Caveolin by Src Tyrosine Kinases , 1996, The Journal of Biological Chemistry.

[28]  H. Lodish,et al.  Molecular Cloning of Caveolin-3, a Novel Member of the Caveolin Gene Family Expressed Predominantly in Muscle (*) , 1996, The Journal of Biological Chemistry.

[29]  H. Lodish,et al.  Identification, sequence, and expression of caveolin-2 defines a caveolin gene family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Lisanti,et al.  Oligomeric structure of caveolin: implications for caveolae membrane organization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Bostwick,et al.  Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. , 1995, Cancer research.

[32]  R. Parton,et al.  De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Zenklusen,et al.  Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. , 1995, Oncogene.

[34]  H. Lodish,et al.  Caveolin Isoforms Differ in Their N-terminal Protein Sequence and Subcellular Distribution. IDENTIFICATION AND EPITOPE MAPPING OF AN ISOFORM-SPECIFIC MONOCLONAL ANTIBODY PROBE (*) , 1995, The Journal of Biological Chemistry.

[35]  F. Vogel,et al.  VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. , 1995, Molecular biology of the cell.

[36]  M. Lisanti,et al.  Evidence for a Regulated Interaction between Heterotrimeric G Proteins and Caveolin , 1995, The Journal of Biological Chemistry.

[37]  I. Bièche,et al.  452 Loss of heterozygosity on 7Q31 occurs early during breast tumorigenesis , 1995 .

[38]  D. Dietzen,et al.  Caveolin Is Palmitoylated on Multiple Cysteine Residues , 1995, The Journal of Biological Chemistry.

[39]  J. Zenklusen,et al.  Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. , 1995, Cancer research.

[40]  P. Troncoso,et al.  Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. , 1994, Cancer research.

[41]  I. Bièche,et al.  (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[42]  H. Lodish,et al.  Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles , 1994, The Journal of cell biology.

[43]  M. Lisanti,et al.  Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. , 1994, Trends in cell biology.

[44]  B. Neel,et al.  Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. , 1993, Analytical biochemistry.

[45]  G. Raposo,et al.  Caveolae and sorting in the trans‐Golgi network of epithelial cells. , 1993, The EMBO journal.

[46]  R. Kurman,et al.  Cytogenetic profile of uterine sarcomas , 1993, Cancer.

[47]  H. Lodish,et al.  Cloning of a Rab3 isotype predominantly expressed in adipocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[48]  I. Bièche,et al.  Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer , 1992, The Lancet.

[49]  N. Severs,et al.  Caveolae: static inpocketings of the plasma membrane, dynamic vesicles or plain artifact? , 1988, Journal of cell science.

[50]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[51]  K. Shiga,et al.  Loss of heterozygosity of chromosome 9p21 and 7q31 is correlated with high incidence of recurrent tumor in head and neck squamous cell carcinoma. , 1998, Anticancer research.